Physician profile
Mark I Macpherson
NPI 1962433805
$1,379.05
in general payments reported to CMS, 2019-2025
21 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $73.58 · 2023: $289 · 2024: $210 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $465.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $121.37 | 2024-2025 | Proclaim, Freestyle Libre 3, Eterna |
| Astrazeneca Pharmaceuticals Lp | $87.77 | 2019-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $79.32 | 2019-2025 | Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $72.58 | 2019-2024 | Shingrix, Arexvy |
| Lilly USA, LLC | $71.96 | 2019-2024 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $61.17 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $53.32 | 2019 | |
| Amgen INC. | $49.26 | 2019-2023 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.13 | 2019-2020 | |
| Abbvie INC. | $44.24 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $37.33 | 2019-2020 | |
| Pfizer INC. | $37.17 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $33.19 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.69 | 2025 | Xifaxan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $20.40 | 2023 | Quviviq |
| Organon LLC | $18.92 | 2024 | |
| Astellas Pharma US INC | $14.74 | 2024 | Veozah |
| Amarin Pharma, INC. | $14.32 | 2019 | |
| Genentech USA, INC. | $14.17 | 2019 | |
| Zyla Life Sciences, INC. | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Macpherson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.